Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, positive-controlled, multicenter study comparing the efficacy of carvedilol phosphate modified release formulation (COREG MR) and metoprolol succinate extended release (Toprol-XL) on the reduction of microalbuminuria [proteinuria] in patients with hypertension and microalbuminuria

Next Previous
X
Search
Trial Profile

A randomized, double-blind, positive-controlled, multicenter study comparing the efficacy of carvedilol phosphate modified release formulation (COREG MR) and metoprolol succinate extended release (Toprol-XL) on the reduction of microalbuminuria [proteinuria] in patients with hypertension and microalbuminuria

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carvedilol (Primary) ; Metoprolol
  • Indications Hypertension; Proteinuria
  • Focus Pharmacodynamics
  • Sponsors GSK

    • Most Recent Events

    • 20 Oct 2016 Status changed from completed to discontinued.
    • 01 Oct 2010 Actual end date (May 2006) added as reported by ClinicalTrials.gov.
    • 14 Oct 2008 Status changed from discontinued to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top